Related Experiment Video
Updated: Aug 9, 2026

The Forced Swim Test as a Model of Depressive-like Behavior
Published on: March 2, 2015
Lack of pineal beta-adrenergic receptor alterations in suicide victims with major depression
K Y Little1, J Ranc, J Gilmore
1Department of Psychiatry, University of Michigan School of Medicine, Ann Arbor, USA. kylittle@umich.edu
Abstract:
Noradrenergic function may be altered in depressive illness and thereby contribute to decreased pineal production of melatonin levels, as previously described in some depressed subjects. In the present study, the hypothesis was tested that pineal beta-adrenergic binding would be increased in persons committing suicide with evidence of depressive disorders, reflecting diminished noradrenergic input. Initially, post-mortem human pineal glands were obtained at autopsy. Diagnostic and symptomatic information was then systematically collected from family members using standardized interview techniques. Seven subjects who committed suicide and suffered from major depression, and without exposure to treatment for depressive symptoms were age- and sex-matched with control subjects. Pineal beta-adrenergic binding was assessed by quantitative autoradiography employing four concentrations of [125I]pindolol. Because of possibly complex adrenergic regulation of the pineal, beta-adrenergic receptor binding were subtyped using the selective blocker ICI 89406. No differences in beta-adrenergic receptors were detected between subjects with major depression compared to the matched controls.
More Related Videos
06:55An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents
Published on: December 2, 2015
04:33Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder
Published on: April 26, 2024
Related Concept Videos
G-protein Coupled Receptors
Long-term Depression
Long-term Depression
Calcium Ion Concentration Mechanism
If over time, all...
Drugs Affecting Neurotransmitter Release or Uptake
Depression: Overview
Antidepressant Drugs: MAOIs and Other Agents